(Q38244651)

31 August 2017

title

Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies (English)

1 reference

31 August 2017

0 references

1 reference

Xiaofan Li

1

1 reference

31 August 2017

Daryl Shorter

series ordinal

2

1 reference

31 August 2017

Thomas R Kosten

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

29 August 2014

1 reference

Expert Opinion on Pharmacotherapy

31 August 2017

published in

1 reference

31 August 2017

volume

15

1 reference

31 August 2017

issue

15

1 reference

31 August 2017

page(s)

2263-2275

1 reference

Extent of illicit drug use and dependence, and their contribution to the global burden of disease

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Methadone maintenance treatment: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

French field experience with buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Clinical pharmacology of buprenorphine: ceiling effects at high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine: how to use it right

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Outcome of heroin-dependent adolescents presenting for opiate substitution treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine use in pregnant opioid users: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Acute liver and renal failure during treatment with buprenorphine at therapeutic dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Association between gene variants and response to buprenorphine maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Barriers to primary care physicians prescribing buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Office-based management of opioid dependence with buprenorphine: clinical practices and barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Consumer attitudes about opioid addiction treatment: a focus group study in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Twelve-year trend in treatment seeking for buprenorphine abuse in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Integrating buprenorphine treatment into office-based practice: a qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Factors affecting willingness to provide buprenorphine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Abuse and diversion of buprenorphine sublingual tablets and film.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

An injection depot formulation of buprenorphine: extended bio-delivery and effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Evaluation of an injection depot formulation of buprenorphine: placebo comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Selective review and commentary on emerging pharmacotherapies for opioid addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

A buprenorphine education and training program for primary care residents: implementation and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Efficacy of continuing medical education to reduce the risk of buprenorphine diversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

A history of being prescribed controlled substances and risk of drug overdose death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Reductions in prescription opioid diversion following recent legislative interventions in Florida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

State policy influence on the early diffusion of buprenorphine in community treatment programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Home- versus office-based buprenorphine inductions for opioid-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Home buprenorphine/naloxone induction in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.955469

10.1517/14656566.2014.955469

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference